Modulators of the vascular endothelin receptor in blood pressure regulation and hypertension

Current Molecular Pharmacology

Volumn 4, Issue 3, 2011, Pages 176-186

  Khalil, Raouf A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Blood pressure; Calcium; Endothelium; Nitric oxide; Smooth muscle

Indexed keywords

2 [[2 [[2 [[(HEXAHYDRO 1H AZEPIN 1 YL)CARBONYL]AMINO] 4 METHYLPENTANOYL]AMINO] 3 (1 METHYL 1H INDOL 3 YL)PROPIONYL]AMINO] 3 (2 PYRIDYL)PROPIONIC ACID; 3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; 4 (1,3 BENZODIOXOL 5 YL) 1 [(2,6 DIETHYLPHENYL)CARBAMOYLMETHYL] 2 (4 PROPOXYPHENYL) 3 PYRROLIDINECARBOXYLIC ACID; 4 (4 METHOXYPHENYL) 2 (3,4 METHYLENEDIOXYPHENYL) 4 OXO 3 (3,4,5 TRIMETHOXYBENZYL) 2 BUTENOIC ACID; 5 DIMETHYLAMINO N (3,4 DIMETHYL 5 ISOXAZOLYL) 1 NAPHTHALENESULFONAMIDE; AMBRISENTAN; ATRASENTAN; BOSENTAN; BQ 610; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DARUSENTAN; DIACYLGLYCEROL; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; HYPERTENSIVE AGENT; MITOGEN ACTIVATED PROTEIN KINASE; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; N ACETYL 10,11 DIHYDRO 5H DIBENZO[A,D]CYCLOHEPTEN 5 YLGLYCYLLEUCYLASPARTYLISOLEUCYLISOLEUCYLTRYPTOPHAN; N ACETYL 3,3 DIPHENYL DEXTRO ALANYLLEUCYLASPARTYLISOLEUCYLISOLEUCYLTRYPTOPHAN; N(G) NITROARGININE METHYL ESTER; PREPROENDOTHELIN 1; PROTEIN KINASE C; SARAFOTOXIN S6C; SUCCINYLENDOTHELIN 1 [8-21][9 GLUTAMIC ACID 11,15 ALANINE]; TUMOR NECROSIS FACTOR ALPHA; VASOACTIVE AGENT;

ARTICLE; BLOOD PRESSURE REGULATION; BLOOD VESSEL REACTIVITY; BLOOD VESSEL TONE; DRUG CLEARANCE; DRUG METABOLISM; DRUG SYNTHESIS; GENETIC TRANSCRIPTION; HUMAN; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; RESISTANCE BLOOD VESSEL; SIGNAL TRANSDUCTION;

BLOOD PRESSURE; ENDOTHELIAL CELLS; ENDOTHELINS; HUMANS; HYPERTENSION; MUSCLE, SMOOTH, VASCULAR; PROTEIN ISOFORMS; RECEPTORS, ENDOTHELIN; SIGNAL TRANSDUCTION;

EID: 80053539465     PISSN: 18744672     EISSN: 18744702     Source Type: Journal    
DOI: 10.2174/1874467211104030176     Document Type: Article

References (85)

1. Napoli, C.; Ignarro, L.J. Nitric oxide and pathogenic mechanisms involved in the development of vascular diseases. Arch. Pharm. Res., 2009, 32(8), 1103-1108.
2. Fleming, I.; Busse, R. NO: the primary EDRF. J. Mol. Cell Cardiol., 1999, 31(1), 5-14.
3. Mitchell, J.A.; Ali, F.; Bailey, L.; Moreno, L.; Harrington, L.S. Role of nitric oxide and prostacyclin as vasoactive hormones released by the endothelium. Exp. Physiol., 2008, 93(1), 141-147.
4. Feletou, M.; Vanhoutte, P.M. Endothelium-derived hyperpolarizing factor: where are we now? Arterioscler. Thromb. Vasc. Biol., 2006, 26(6), 1215-1225.
5. Yanagisawa, M.; Kurihara, H.; Kimura, S.; Tomobe, Y.; Kobayashi, M.; Mitsui, Y.; Yazaki, Y.; Goto, K.; Masaki, T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature, 1988, 332(6163), 411-415.
6. Pollock, J.S.; Pollock, D.M. Endothelin and NOS1/nitric oxide signaling and regulation of sodium homeostasis. Curr. Opin. Nephrol. Hypertens., 2008, 17(1), 70-75.
7. Granger, J.P.; Abram, S.; Stec, D.; Chandler, D.; LaMarca, B. Endothelin, the kidney, and hypertension. Curr. Hypertens. Rep., 2006, 8(4), 298-303.
8. Hynynen, M.M.; Khalil, R.A. The vascular endothelin system in hypertension--recent patents and discoveries. Recent Pat. Cardiovasc. Drug Discov., 2006, 1(1), 95-108.
9. Schiffrin, E.L. Vascular endothelin in hypertension. Vascul. Pharmacol., 2005, 43(1), 19-29.
10. Pollock, D.M. Renal endothelin in hypertension. Curr. Opin. Nephrol. Hypertens., 2000, 9(2), 157-164.
11. Dhaun, N.; Pollock, D.M.; Goddard, J.; Webb, D.J. Selective and mixed endothelin receptor antagonism in cardiovascular disease. Trends Pharmacol. Sci., 2007, 28(11), 573-579.
12. Krum, H.; Viskoper, R.J.; Lacourciere, Y.; Budde, M.; Charlon, V. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N. Engl. J. Med., 1998, 338(12), 784-790.
13. Luscher, T.F.; Barton, M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation, 2000, 102(19), 2434-2440.
14. Rubanyi, G.M.; Botelho, L.H. Endothelins. FASEB J., 1991, 5(12), 2713-2720.
15. Matsumoto, H.; Suzuki, N.; Onda, H.; Fujino, M. Abundance of endothelin-3 in rat intestine, pituitary gland and brain. Biochem. Biophys. Res. Commun., 1989, 164(1), 74-80.
16. Cunningham, M.E.; Huribal, M.; Bala, R.J.; McMillen, M.A. Endothelin- 1 and endothelin-4 stimulate monocyte production of cytokines. Crit. Care Med., 1997, 25(6), 958-964.
17. Kawana, M.; Lee, M.E.; Quertermous, E.E.; Quertermous, T. Cooperative interaction of GATA-2 and AP1 regulates transcription of the endothelin-1 gene. Mol. Cell Biol., 1995, 15(8), 4225-4231.
18. Jeng, A.Y.; Mulder, P.; Kwan, A.L.; Battistini, B. Nonpeptidic endothelin-converting enzyme inhibitors and their potential therapeutic applications. Can. J. Physiol. Pharmacol., 2002, 80(5), 440-449.
19. Yanagisawa, H.; Hammer, R.E.; Richardson, J.A.; Emoto, N.; Williams, S.C.; Takeda, S.; Clouthier, D.E.; Yanagisawa, M. Disruption of ECE-1 and ECE-2 reveals a role for endothelinconverting enzyme-2 in murine cardiac development. J. Clin. Invest., 2000, 105(10), 1373-1382.
20. Schiffrin, E.L.; Touyz, R.M. Vascular biology of endothelin. J. Cardiovasc. Pharmacol., 1998, 32(Suppl. 3), S2-13.
21. Emori, T.; Hirata, Y.; Imai, T.; Ohta, K.; Kanno, K.; Eguchi, S.; Marumo, F. Cellular mechanism of thrombin on endothelin-1 biosynthesis and release in bovine endothelial cell. Biochem. Pharmacol., 1992, 44(12), 2409-2411.
22. Yoshimoto, S.; Ishizaki, Y.; Sasaki, T.; Murota, S. Effect of carbon dioxide and oxygen on endothelin production by cultured porcine cerebral endothelial cells. Stroke, 1991, 22(3), 378-383.
23. Malek, A.M.; Zhang, J.; Jiang, J.; Alper, S.L.; Izumo, S. Endothelin- 1 gene suppression by shear stress: pharmacological evaluation of the role of tyrosine kinase, intracellular calcium, cytoskeleton, and mechanosensitive channels. J. Mol. Cell Cardiol., 1999, 31(2), 387-399.
24. Boulanger, C.; Luscher, T.F. Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J. Clin. Invest., 1990, 85(2), 587-590.
25. Kohno, M.; Yokokawa, K.; Horio, T.; Yasunari, K.; Murakawa, K.; Takeda, T. Atrial and brain natriuretic peptides inhibit the endothelin- 1 secretory response to angiotensin II in porcine aorta. Circ. Res., 1992, 70(2), 241-247.
26. van Mourik, J.A.; Romani de Wit, T.; Voorberg, J. Biogenesis and exocytosis of Weibel-Palade bodies. Histochem. Cell Biol., 2002, 117(2), 113-122.
27. Shichiri, M.; Hirata, Y.; Ando, K.; Emori, T.; Ohta, K.; Kimoto, S.; Ogura, M.; Inoue, A.; Marumo, F. Plasma endothelin levels in hypertension and chronic renal failure. Hypertension, 1990, 15(5), 493-496.
28. Abdel-Sayed, S.; Brunner, H.R.; Nussberger, J. Volume expansion enhances plasma endothelin-1. Am J Hypertens., 2003, 16(12), 1057-1061.
29. Zhao, H.; Joshua, I.G.; Porter, J.P. Microvascular responses to endothelin in deoxycorticosterone acetate-salt hypertensive rats. Am. J. Hypertens., 2000, 13(7), 819-826.
30. Cantaro, S.; Milan Manani, S.; Marcon, R.; Bonfante, L.; Masiero, M.; D'Angelo, A.; Calo, L. Urinary excretion of vasoactive substances in chronic renal failure. Clin. Nephrol., 2001, 55(5), 393-399.
31. Modesti, P.A.; Cecioni, I.; Costoli, A.; Poggesi, L.; Galanti, G.; Serneri, G.G. Renal endothelin in heart failure and its relation to sodium excretion. Am. Heart J., 2000, 140(4), 617-622.
32. Kedzierski, R.M.; Yanagisawa, M. Endothelin system: the doubleedged sword in health and disease. Annu. Rev. Pharmacol. Toxicol., 2001, 41, 851-876.
33. Abassi, Z.A.; Tate, J.E.; Golomb, E.; Keiser, H.R. Role of neutral endopeptidase in the metabolism of endothelin. Hypertension, 1992, 20(1), 89-95.
34. Ponnuchamy, B.; Khalil, R.A. Cellular mediators of renal vascular dysfunction in hypertension. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2009, 296(4), R1001-R1018.
35. Ohuchi, T.; Yanagisawa, M.; Gariepy, C.E. Renal tubular effects of endothelin-B receptor signaling: its role in cardiovascular homeostasis and extracellular volume regulation. Curr. Opin. Nephrol. Hypertens., 2000, 9(4), 435-439.
36. Hopfner, R.L.; Hasnadka, R.V.; Wilson, T.W.; McNeill, J.R.; Gopalakrishnan, V. Insulin increases endothelin-1-evoked intracellular free calcium responses by increased ET(A) receptor expression in rat aortic smooth muscle cells. Diabetes, 1998, 47(6), 937-944.
37. Redmond, E.M.; Cahill, P.A.; Hodges, R.; Zhang, S.; Sitzmann, J.V. Regulation of endothelin receptors by nitric oxide in cultured rat vascular smooth muscle cells. J. Cell Physiol., 1996, 166(3), 469-479.
38. Schiffrin, E.L. Endothelin: potential role in hypertension and vascular hypertrophy. Hypertension, 1995, 25(6), 1135-1143.
39. Schneider, M.P.; Boesen, E.I.; Pollock, D.M. Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease. Annu. Rev. Pharmacol. Toxicol., 2007, 47, 731-759.
40. Watts, S.W. Endothelin receptors: what's new and what do we need to know? Am. J. Physiol. Regul. Integr. Comp. Physiol., 2010, 298(2), R254-R260.
41. Tykocki, N.R.; Gariepy, C.E.; Watts, S.W. Endothelin ET(B) receptors in arteries and veins: multiple actions in the vein. J. Pharmacol. Exp. Ther., 2009, 329(3), 875-881.
42. Gariepy, C.E.; Ohuchi, T.; Williams, S.C.; Richardson, J.A.; Yanagisawa, M. Salt-sensitive hypertension in endothelin-B receptordeficient rats. J. Clin. Invest., 2000, 105(7), 925-933.
43. Tostes, R.C.; Touyz, R.M.; He, G.; Chen, X.; Schiffrin, E.L. Contribution of endothelin-1 to renal activator protein-1 activation and macrophage infiltration in aldosterone-induced hypertension. Clin. Sci. (Lond), 2002, 103(Suppl 48), 25S-30S.
44. Bkaily, G.; Choufani, S.; Sader, S.; Jacques, D.; d'Orleans-Juste, P.; Nader, M.; Kurban, G.; Kamal, M. Activation of sarcolemma and nuclear membranes ET-1 receptors regulates transcellular calcium levels in heart and vascular smooth muscle cells. Can. J. Physiol. Pharmacol., 2003, 81(6), 654-662.
45. McMurdo, L.; Thiemermann, C.; Vane, J.R. The endothelin ETB receptor agonist, IRL 1620, causes vasodilatation and inhibits ex vivo platelet aggregation in the anaesthetised rabbit. Eur. J. Pharmacol., 1994, 259(1), 51-55.
46. Nakashima, M.; Vanhoutte, P.M. Endothelin-1 and -3 cause endothelium- dependent hyperpolarization in the rat mesenteric artery. Am. J. Physiol., 1993, 265(6 Pt 2), H2137-H2141.
47. Tirapelli, C.R.; Casolari, D.A.; Yogi, A.; Montezano, A.C.; Tostes, R.C.; Legros, E.; D'Orleans-Juste, P.; de Oliveira, A.M. Functional characterization and expression of endothelin receptors in rat carotid artery: involvement of nitric oxide, a vasodilator prostanoid and the opening of K+ channels in ETB-induced relaxation. Br. J. Pharmacol., 2005, 146(6), 903-912.
48. Neylon, C.B. Vascular biology of endothelin signal transduction. Clin. Exp. Pharmacol. Physiol., 1999, 26(2), 149-153.
49. Smith, L.; Payne, J.A.; Sedeek, M.H.; Granger, J.P.; Khalil, R.A. Endothelin-induced increases in Ca2+ entry mechanisms of vascular contraction are enhanced during high-salt diet. Hypertension, 2003, 41(3 Pt. 2), 787-793.
50. Chew, D.K.; Orshal, J.M.; Khalil, R.A. Elastase-induced suppression of endothelin-mediated Ca2+ entry mechanisms of vascular contraction. Hypertension, 2003, 42(4), 818-824.
51. McNair, L.L.; Salamanca, D.A.; Khalil, R.A. Endothelin-1 promotes Ca2+ antagonist-insensitive coronary smooth muscle contraction via activation of epsilon-protein kinase C. Hypertension, 2004, 43(4), 897-904.
52. Sirous, Z.N.; Fleming, J.B.; Khalil, R.A. Endothelin-1 enhances eicosanoids-induced coronary smooth muscle contraction by activating specific protein kinase C isoforms. Hypertension, 2001, 37(2 Pt. 2), 497-504.
53. Kanashiro, C.A.; Altirkawi, K.A.; Khalil, R.A. Preconditioning of coronary artery against vasoconstriction by endothelin-1 and prostaglandin F2alpha during repeated downregulation of epsilonprotein kinase C. J. Cardiovasc. Pharmacol., 2000, 35(3), 491-501.
54. Cain, A.E.; Tanner, D.M.; Khalil, R.A. Endothelin-1--induced enhancement of coronary smooth muscle contraction via MAPKdependent and MAPK-independent [Ca(2+)](i) sensitization pathways. Hypertension, 2002, 39(2 Pt. 2), 543-549.
55. Perry, M.G.; Molero, M.M.; Giulumian, A.D.; Katakam, P.V.; Pollock, J.S.; Pollock, D.M.; Fuchs, L.C. ET(B) receptor-deficient rats exhibit reduced contraction to ET-1 despite an increase in ET(A) receptors. Am. J. Physiol. Heart. Circ. Physiol., 2001, 281(6), H2680-H2686.
56. Schroeder, A.C.; Imig, J.D.; LeBlanc, E.A.; Pham, B.T.; Pollock, D.M.; Inscho, E.W. Endothelin-mediated calcium signaling in preglomerular smooth muscle cells. Hypertension, 2000, 35(1 Pt. 2), 280-286.
57. Schiffrin, E.L. Role of endothelin-1 in hypertension and vascular disease. Am. J. Hypertens., 2001, 14(6 Pt. 2), 83S-89S.
58. McCulloch, K.M.; MacLean, M.R. EndothelinB receptor-mediated contraction of human and rat pulmonary resistance arteries and the effect of pulmonary hypertension on endothelin responses in the rat. J. Cardiovasc. Pharmacol., 1995, 26(Suppl. 3), S169-176.
59. Berthiaume, N.; Yanagisawa, M.; D'Orleans-Juste, P. Contribution of endogenous endothelin-1 and endothelin-A-receptors to the hypertensive state of endothelin-B heterozygous (+/-) knockout mice. J. Cardiovasc. Pharmacol., 2000, 36(5 Suppl. 1), S72-74.
60. Murakoshi, N.; Miyauchi, T.; Kakinuma, Y.; Ohuchi, T.; Goto, K.; Yanagisawa, M.; Yamaguchi, I. Vascular endothelin-B receptor system in vivo plays a favorable inhibitory role in vascular remodeling after injury revealed by endothelin-B receptor-knockout mice. Circulation, 2002, 106(15), 1991-1998.
61. Vassileva, I.; Mountain, C.; Pollock, D.M. Functional role of ETB receptors in the renal medulla. Hypertension, 2003, 41(6), 1359-1363.
62. Maguire, J.J.; Kuc, R.E.; Davenport, A.P. Vasoconstrictor activity of novel endothelin peptide, ET-1(1 - 31), in human mammary and coronary arteries in vitro. Br. J. Pharmacol., 2001, 134(6), 1360-1366.
63. Zhou, Y.; Dirksen, W.P.; Zweier, J.L.; Periasamy, M. Endothelin- 1-induced responses in isolated mouse vessels: the expression and function of receptor types. Am. J. Physiol. Heart Circ. Physiol., 2004, 287(2), H573-H578.
64. Watts, S.W.; Fink, G.D.; Northcott, C.A.; Galligan, J.J. Endothelin- 1-induced venous contraction is maintained in DOCA-salt hypertension; studies with receptor agonists. Br. J. Pharmacol., 2002, 137(1), 69-79.
65. Giardina, J.B.; Green, G.M.; Rinewalt, A.N.; Granger, J.P.; Khalil, R.A. Role of endothelin B receptors in enhancing endotheliumdependent nitric oxide-mediated vascular relaxation during high salt diet. Hypertension, 2001, 37(2 Pt. 2), 516-523.
66. Touyz, R.M.; Schiffrin, E.L. Role of endothelin in human hypertension. Can. J. Physiol. Pharmacol., 2003, 81(6), 533-541.
67. Schiffrin, E.L. Endothelin and endothelin antagonists in hypertension. J. Hypertens., 1998, 16(12 Pt. 2), 1891-1895.
68. Pollock, D.M.; Pollock, J.S. Evidence for endothelin involvement in the response to high salt. Am. J. Physiol. Renal Physiol., 2001, 281(1), F144-F150.
69. Nguyen, P.V.; Parent, A.; Deng, L.Y.; Fluckiger, J.P.; Thibault, G.; Schiffrin, E.L. Endothelin vascular receptors and responses in deoxycorticosterone acetate-salt hypertensive rats. Hypertension, 1992, 19(Suppl. 2), II98-104.
70. de Groot, M.C.; Illing, B.; Horn, M.; Urban, B.; Haase, A.; Schnackerz, K.; Neubauer, S. Endothelin-1 increases susceptibility of isolated rat hearts to ischemia/reperfusion injury by reducing coronary flow. J. Mol. Cell Cardiol., 1998, 30(12), 2657-2668.
71. Barman, S.A. Vasoconstrictor effect of endothelin-1 on hypertensive pulmonary arterial smooth muscle involves Rho-kinase and protein kinase C. Am. J. Physiol. Lung Cell Mol. Physiol., 2007, 293(2), L472-L479.
72. McCulloch, K.M.; Docherty, C.; MacLean, M.R. Endothelin receptors mediating contraction of rat and human pulmonary resistance arteries: effect of chronic hypoxia in the rat. Br. J. Pharmacol., 1998, 123(8), 1621-1630.
73. Tostes, R.C.; Wilde, D.W.; Bendhack, L.M.; Webb, R.C. Calcium handling by vascular myocytes in hypertension. Braz. J. Med. Biol. Res., 1997, 30(3), 315-323.
74. Matsumura, Y.; Hashimoto, N.; Taira, S.; Kuro, T.; Kitano, R.; Ohkita, M.; Opgenorth, T.J.; Takaoka, M. Different contributions of endothelin-A and endothelin-B receptors in the pathogenesis of deoxycorticosterone acetate-salt-induced hypertension in rats. Hypertension, 1999, 33(2), 759-765.
75. Pollock, D.M. Chronic studies on the interaction between nitric oxide and endothelin in cardiovascular and renal function. Clin. Exp. Pharmacol. Physiol., 1999, 26(3), 258-261.
76. Larouche, I.; Schiffrin, E.L. Cardiac microvasculature in DOCAsalt hypertensive rats: effect of endothelin ET(A) receptor antagonism. Hypertension, 1999, 34(4 Pt. 2), 795-801.
77. Luscher, T.F.; Enseleit, F.; Pacher, R.; Mitrovic, V.; Schulze, M.R.; Willenbrock, R.; Dietz, R.; Rousson, V.; Hurlimann, D.; Philipp, S.; Notter, T.; Noll, G.; Ruschitzka, F. Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT). Circulation, 2002, 106(21), 2666-2672.
78. Hurlimann, D.; Enseleit, F.; Noll, G.; Luscher, T.F.; Ruschitzka, F. Endothelin antagonists and heart failure. Curr. Hypertens. Rep., 2002, 4(1), 85-92.
79. Jacobs, W.; Boonstra, A.; Brand, M.; Rosenberg, D.M.; Schaaf, B.; Postmus, P.E.; Vonk Noordegraaf, A. Long-term outcomes in pulmonary arterial hypertension in the first-line epoprostenol or firstline bosentan era. J. Heart Lung. Transplant., 2010, 29(10), 1150-1158.
80. Blalock, S.E.; Matulevicius, S.; Mitchell, L.C.; Reimold, S.; Warner, J.; Peshock, R.; Torres, F.; Chin, K.M. Long-term outcomes with ambrisentan monotherapy in pulmonary arterial hypertension. J. Card. Fail., 2010, 16(2), 121-127.
81. Croxtall, J.D.; Keam, S.J. Ambrisentan. Drugs, 2008, 68(15), 2195-2204.
82. Mortensen, L.H.; Fink, G.D. Captopril prevents chronic hypertension produced by infusion of endothelin-1 in rats. Hypertension, 1992, 19(6 Pt. 2), 676-680.
83. Wong, J.; Fineman, J.R.; Heymann, M.A. The role of endothelin and endothelin receptor subtypes in regulation of fetal pulmonary vascular tone. Pediatr. Res., 1994, 35(6), 664-670.
84. Callera, G.E.; Touyz, R.M.; Teixeira, S.A.; Muscara, M.N.; Carvalho, M.H.; Fortes, Z.B.; Nigro, D.; Schiffrin, E.L.; Tostes, R.C. ETA receptor blockade decreases vascular superoxide generation in DOCA-salt hypertension. Hypertension, 2003, 42(4), 811-817.
85. Sullivan, J.C.; Pollock, D.M.; Pollock, J.S. Altered nitric oxide synthase 3 distribution in mesenteric arteries of hypertensive rats. Hypertension, 2002, 39(2 Pt. 2), 597-602.